Wellgistics Health, Inc. operates as a holding company centered around pharmaceuticals and healthcare services. The company is headquartered in Tampa, Florida. The company went IPO on 2025-02-21. The company focuses on specialty medications and a community-based model offering home delivery services to patients. The company is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows for clinical services to be connected to the Company’s health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, improve prescription price transparency, and provide additional concierge services. Its products include Kyzatrex and Semaglutide and Tirzepatide.
최신 재무제표(Form-10K)에 따르면, Wellgistics Health Inc의 총 자산은 $0이며, 순損失입니다.
WGRX의 주요 재무 비율은 무엇인가요?
Wellgistics Health Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Wellgistics Health Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Wellgistics Health Inc の最大収益セグメントは Drilling and Evaluation で、最新の利益発表における収益は 1,371,000,000 です。地域別に見ると、North America が Wellgistics Health Inc の主要市場であり、収益は 983,000,000 です。
Wellgistics Health Inc은 수익성이 있나요?
いいえ, 최신 재무제표에 따르면 Wellgistics Health Inc의 순損失은 $0입니다.